Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
Amarin Corporation plc (NASDAQ:AMRN), today announced support for an investigator-initiated trial to study the effects of icosapent ethyl (VASCEPA®) (IPE) on
Amarin : Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and Flu, and the Clinical Severity of Such Infections | MarketScreener
04:12pm, Friday, 07'th Aug 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for an investigator-initiated trial to study the effects of icos
U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children
12:00am, Friday, 07'th Aug 2020
Bayer announced today that the United States Food and Drug Administration (FDA) has approved Lampit® (nifurtimox) for use in pediatric patients (from
Amarin Earnings, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:AMRN)
09:11pm, Thursday, 06'th Aug 2020
Amarin reports better than expected financial numbers for second quarter. CytoDyn reports positive DSMC opinion for COVID-19 trial.
Amarin Corporation plc (AMRN) Q2 2020 Earnings Call Transcript | AlphaStreet
01:35am, Thursday, 06'th Aug 2020
Amarin Corporation plc (NASDAQ: AMRN) Q2 2020 earnings call dated Aug. 04, 2020 Corporate Participants: Elisabeth Schwartz -- Senior Director of Investor Relations John Thero -- President and Chie
Amarin: Improving HCP Access Should Drive More Vascepa Sales, Says Analyst
12:19am, Thursday, 06'th Aug 2020
Keeping it simple, biotech Amarin (AMRN) has one product. This means the company can focus solely on the progress of its high triglycerides treatment, Vascepa.However, the drawbacks of having only one
Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe
03:42pm, Wednesday, 05'th Aug 2020
Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Amarin (AMRN) Q2 2020 earnings call: Focus was mainly on VASCEPA litigation | AlphaStreet
10:45am, Wednesday, 05'th Aug 2020
Amarin (NASDAQ: AMRN) reported second quarter 2020 results yesterday. During the earnings conference call, the management and the analysts discussed mainly the ongoing VASCEPA litigation
4 Reasons Amarin Stock Could Tumble Even Further
10:23am, Wednesday, 05'th Aug 2020
Amarin (NASDAQ: AMRN) investors who had been expecting a sales explosion have instead seen the bottom fall out from under their shares, and the company's second-quarter earnings report was less than e
With Biotech Stocks, Investors Love the Thrill of the Chase
09:30am, Wednesday, 05'th Aug 2020
Individual investors are placing their bets on biotech companies pursuing coronavirus advances. Some invest for fun and profit, while others want to be a part of a historic breakthrough.
Amarin (AMRN) Q2 2020 Earnings Call Transcript | The Motley Fool
02:01am, Wednesday, 05'th Aug 2020
AMRN earnings call for the period ending June 30, 2020.
Texas medical board warns physicians who claim COVID-19 cure
08:16pm, Tuesday, 04'th Aug 2020
The Texas board that licenses doctors has warned physicians that it could take action against anyone who falsely advertises a cure for COVID-19
Amarin Corporation plc's (AMRN) CEO John Thero on Q2 2020 Results - Earnings Call Transcript
06:58pm, Tuesday, 04'th Aug 2020
Amarin Corporation plc (NASDAQ:AMRN) Q2 2020 Earnings Conference Call August 4, 2020 7:30 AM ET Company Participants Elisabeth Schwartz - Senior Director, Investor Relations John Thero - President and
Amarin Reports Mixed Q2 As COVID-19 Weighs On Results; Analyst Sees Favorable Risk-Reward
06:10pm, Tuesday, 04'th Aug 2020
Amarin Corporation plc (NASDAQ: AMRN) shares were advancing strongly Tuesday following the release Tuesday of second-quarter results. What Happened: Amarin reported second-quarter revenue of $135.3 m
